Slide 1: Historical Consolidated Results of Operations
Historical Consolidated Results of Operations (Reflecting the Surgical Business) November 2025 1
Slide 2: Reconciliation to Adjusted EBITDA
Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Net income (loss) from continuing operations $ 834,493 $ (180,488) $ 714,186 $ (2,872,286) Adjustments: Interest expense
Slide 3: Consolidated Results of Operations
Consolidated results of operations (reflecting our surgical business) for the periods indicated below (Unaudited) 2025 2024 2023 Q1 Q2 Q3 YTD Q1 Q2 Q3 Q4 YTD Q1 Q2 Q3 Q4 YTD Net Revenue $23,434,096 $25,804,252 $26,333,819 $75,572,167 $18,536,638 $20,158,823 $21,671,599 $26,305,365 $86,672,425 $15,51
Slide 4: Reconciliation to Adjusted EBITDA
Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA for the periods indicated below (Unaudited) 2025 2024 2023 Q1 Q2 Q3 YTD Q1 Q2 Q3 Q4 YTD Q1 Q2 Q3 Q4 YTD Net income (loss) from continuing operations $ (620,566) $ 500,259 $ 834,493 $ 714,186 $ (477,485) $(2,214,313) $
Slide 5: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this press release and on the related teleconference call, including Ad